Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
grade A 86.3 -0.46% -0.40
ARGX closed down 0.46 percent on Wednesday, April 25, 2018, on 41 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
Intraday Alerts Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ARGX trend table...

Date Alert Name Type % Chg
Apr 25 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Apr 25 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Apr 25 Overbought Stochastic Strength 0.00%
Apr 25 Down 3 Days in a Row Weakness 0.00%
Apr 25 Down 4 Days in a Row Weakness 0.00%
Apr 24 1,2,3 Pullback Bullish Bullish Swing Setup -0.46%
Apr 24 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.46%
Apr 24 Narrow Range Bar Range Contraction -0.46%
Apr 24 NR7 Range Contraction -0.46%
Apr 24 Overbought Stochastic Strength -0.46%

Older signals for ARGX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
  • Earnings date: 2017-10-26
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Is ARGX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Apr 26 Blog Exposure - Argenx to Present Complete Data from Phase-2 Clinical Trial of Efgartigimod (ARGX-113) at AAN Annual Meeting
Apr 25 Argenx (ARGX) Phase2 Study Of Efgartigimod In Patients With Generalized Myasthenia Gravis - Slideshow
Apr 24 argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting
Apr 12 Argenx to receive third milestone payment associated with CTA approval for ARGX-112
Apr 12 argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112
Apr 9 Benzinga's Top Upgrades, Downgrades For April 9, 2018
Apr 9 Premarket analyst action - healthcare
Apr 9 Argenx appoints Keith Woods as COO
Apr 9 argenx appoints Keith Woods as Chief Operating Officer
Apr 3 argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
See more ARGX news...
Indicators
Indicator Value
52 Week High 90.2
52 Week Low 17.33
Average Volume 146,280
200-Day Moving Average 46.8712
50-Day Moving Average 81.332
20-Day Moving Average 82.547
10-Day Moving Average 86.791
Average True Range 2.9743
ADX 31.39
+DI 30.88
-DI 15.99
Chandelier Exit (Long, 3 ATRs ) 81.2771
Chandelier Exit (Short, 3 ATRs ) 81.6429
Upper Bollinger Band 91.763
Lower Bollinger Band 73.331
Percent B (%b) 0.7
BandWidth 22.329097
MACD Line 2.3238
MACD Signal Line 1.8879
MACD Histogram 0.4359
Fundamentals Value
Market Cap 2.32 Billion
Num Shares 26.9 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -67.95
Price-to-Sales 15.41
Price-to-Book 3.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 89.15
Resistance 3 (R3) 89.16 88.22 88.68
Resistance 2 (R2) 88.22 87.49 88.22 88.52
Resistance 1 (R1) 87.26 87.05 87.74 87.25 88.36
Pivot Point 86.32 86.32 86.56 86.32 86.32
Support 1 (S1) 85.36 85.59 85.84 85.35 84.24
Support 2 (S2) 84.42 85.15 84.42 84.08
Support 3 (S3) 83.46 84.42 83.93
Support 4 (S4) 83.45